Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3999400 | Urologic Oncology: Seminars and Original Investigations | 2016 | 8 Pages |
Abstract
Over the past 2 decades, age-adjusted prostate cancer incidence rates in Pennsylvania have decreased, primarily because of the decreased detection of early-stage disease. There has been a corresponding shift toward more advanced disease at diagnosis. These findings may be explained by the decreased use of prostate-specific antigen-based screening, among other factors. The 2012 United States Preventative Services Task Force recommendations against prostate cancer screening may exacerbate this concerning trend, potentially resulting in an increase in prostate cancer-specific mortality.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Adam C. M.D., Sean R. M.D., Susan G. M.S., Ph.D., Jack H. M.D.,